Europe Approves RejuvenAir For COPD With Chronic Bronchitis

CSA Medical, a Boston-based company, has recently announced that it has received European approval of its RejuvenAir treatment system.

The system is designed for the treatment of patients suffering from chronic obstructive pulmonary disease (COPD) with chronic bronchitis.

Chronic bronchitis is a long-term, progressive lung disease which, over time, makes it increasingly difficult for patients to breathe.

It is the largest subset of COPD diseases and is characterised by an inflammation of the bronchial airways, leading to a productive cough due to overproduction of mucus and damaged cilia.

It is considered to be chronic when a patient has experienced symptoms consistently for two consecutive years, and may also present with partially blocked airways due to excess swelling and mucus.

The chronic inflammation, coughing, and mucus production significantly impact sufferers’  quality of life, and while medications are available that help reduce symptoms, they do not address the disease itself.

RejuvenAir is a revolutionary new treatment system which applies liquid nitrogen at -196ºC to targeted areas of the lungs that have been damaged by the disease.

The extreme cold freezes the epithelial surface layer of the bronchial airways, killing the damaged cells and thus allowing new, healthy cells to grow.

This results in long-term improvements in patients’  lung function.

Before approving the system, the EU carried out a study on 35 patients, and found the treatment improved patient quality of life without any significant risks.

Professor Pallav Shah, M.D., F.R.C.P. from the Royal Brompton Hospital in London, said the treatment “can be safely delivered in patients with COPD and demonstrates clinical meaningful improvements in quality of life and patient-reported outcome scores out to 12 months.

“This is a promising new therapy for the millions of people who suffer from chronic bronchitis.”

For calibration of medical equipment and medical device testing, get in touch with us today.

Leave a Comment

Your email address will not be published. Required fields are marked *